BioMerieux snares stake in Knome

France's BioMerieux has acquired a 10 percent stake in Knome for $5 million and struck a deal to use the Cambridge, MA-based company's genome sequencing and analysis services. "The deal with Knome allows the group to strengthen its position in molecular biology and to create diagnostic tools for tomorrow," CM-CIC Securities analyst Arsene Guekam said in a research note. Story

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.